Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 10/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30302079 | 1.00 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRNA7PRKCIHTR1A | |
| SCHEMBL16675855 | 0.95 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNA7PRKCIHTR1A | |
| SCHEMBL16135204 | 0.83 | HTR1A (0.44) | CHRNB4CHRNA3CHRNA7HTR1AACMSD | |
| SCHEMBL5387084 | 0.83 | HTR1A (0.44) | HTR1AACMSDENPP2CDK8 | |
| SCHEMBL23015504 | 0.79 | HTR1A (0.47) | HTR1AACMSD | |
| SCHEMBL9455150 | 0.79 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNA7PRKCIACMSD | |
| SCHEMBL677309 | 0.77 | HTR1A (0.46) | CHRNB4CHRNA3CHRNA7HTR1AACMSD | |
| SCHEMBL5269419 | 0.77 | ACMSD (0.50) | CHRNB4CHRNA3ACMSD | |
| SCHEMBL11862219 | 0.76 | ACMSD (0.47) | CHRNB4CHRNA3CHRNA7ACMSD | |
| SCHEMBL9455057 | 0.76 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNA7PRKCIACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-116473965-A | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-7235568-B2 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-06-26 | — | — | US | disclosed |
| US-7235568-B2 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-06-26 | — | — | US | disclosed |
| US-7163957-B2 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-01-16 | — | — | US | disclosed |
| US-7163957-B2 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-01-16 | — | — | US | disclosed |
| US-7163957-B2 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-01-16 | — | — | US | disclosed |
| US-20060264471-A1 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2006-11-23 | — | — | US | disclosed |
| EP-1551821-B1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PF MEDICAMENT (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-20060014827-A1 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1551821-A1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035561-A1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264471-A1 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia | CNR2, CNR1, DBH | CHRNB4 114/4885CHRNA3 6/4885CHRNA7 134/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | CHRNB4 4068/4885CHRNA3 3009/4885CHRNA7 3903/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | CHRNB4 4074/4885CHRNA3 3130/4885CHRNA7 3957/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | CHRNB4 4074/4885CHRNA3 3130/4885CHRNA7 3957/4885 |
| US-20060014827-A1 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | CHRNA3, CHRNB3, CNR2 | CHRNB4 44/4885CHRNA3 1/4885CHRNA7 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.